For the quarter ending 2025-09-30, ELTX had -$1,475K decrease in cash & cash equivalents over the period. -$11,086K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Depreciation | - | 106 |
| Net loss | -10,083 | -21,770 |
| Depreciation | 49 | 106 |
| Amortization of right-of-use assets, operating leases | 234 | 453 |
| Non-cash interest expense | 384 | 219 |
| Amortization of debt discount | 0 | 35 |
| Costs expensed upon the issuance of warrants | 0 | - |
| Change in fair value of warrant liabilities | 1,811 | 1,366 |
| Stock-based compensation | 698 | 1,227 |
| Loss on issuance of warrants | 0 | 0 |
| Gain on disposal of property and equipment, net | 0 | 0 |
| Prepaid expenses and other current assets | 344 | -1,387 |
| Other long-term prepaid assets | 170 | 0 |
| Accounts payable | -3,544 | 2,827 |
| Accrued expenses | 107 | -3,309 |
| Deferred research obligation | 0 | -1,169 |
| Operating lease liabilities | -228 | -441 |
| Net cash used in operating activities | -11,086 | -19,069 |
| Purchases of property and equipment | 0 | 0 |
| Proceeds from sale of property and equipment | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from issuance of common stock from at-the-market offerings | - | 2,851 |
| Proceeds from issuance of related party convertible note | 0 | - |
| Proceeds from issuance of common stock and common warrants from the january 2025 offering | 0 | 9,143 |
| Proceeds from issuance of common stock and common warrants | 0 | 0 |
| Proceeds from the exercise of common warrants | 950 | 343 |
| Proceeds from issuance of common stock from at-the-market offerings, net of issuance costs | 11,385 | - |
| Proceeds from the june 2025 promissory note, net of issuance costs | 0 | 9,866 |
| Payment of warrant issuance costs | 0 | - |
| Proceeds from the exercise of stock options | 88 | 57 |
| Net cash provided by financing activities | 9,572 | 22,260 |
| Effect of foreign currency on cash and cash equivalents | 39 | 105 |
| Net increase in cash and cash equivalents | -1,475 | 3,296 |
| Cash and cash equivalents at beginning of period | 19,492 | - |
| Cash and cash equivalents at end of period | 21,313 | - |
Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)